Navigation Links
Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
Date:3/29/2008

the European Medicines Agency in February.

About Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited, established in 2005 after the merger of two leading century-old Japanese pharmaceutical companies, is a global pharmaceutical innovator, continuously generating innovative drugs that enrich the quality of life for patients around the world. The company uses its cumulative knowledge and expertise in the fields of cardiovascular disease, cancer, metabolic disorders, and infection as a foundation for developing an abundant product lineup and R&D pipeline.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first in class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs.

P-LLY

This press release contains certain forward-looking statements about the potential of the investigational compound prasugrel (CS-747, LY640315) and reflects Daiichi Sankyo's and Lilly's current beliefs. However, as with any pharmaceutical compound under development, there are substantial risks and uncertainties in the process of development and regulatory review. There is no guarantee that the compound will receive regulatory approval, that the regulatory approval will be for the indication(s) anticipated by the companies, or that later studies and patient experience will be consistent with study findings to date. There is also no guarantee that the compound will prove to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filing with the United States Securities and Exchange Commission and Daiichi Sankyo's filings with the Tokyo Stock Exchange. Daiichi Sankyo and
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
2. St. Jude Study Offers New Hope for Children With Kidney Tumors Deemed Inoperable
3. Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
6. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
7. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
8. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
9. New Study Reports That Physical Therapy Treatment Resolves Symptoms of Urinary Incontinence in Women
10. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
11. Recent Data Study Suggests Cortisol Could Help Alleviate Suffering for Those With Chronic Fatigue Syndrome and Fibromyalgia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)...th Africa, Nov. 26 The 2009 Frost ...ard in the Generic Pharmaceutical Market is presen...ogo: http://www.newscom.com/cgi-bin/prnh/20081117... the following criteria were used to benchmark Cip...rowth strategy and implementation, degree of innov...
(Date:11/25/2009).... 25 Pharmasset, Inc. (N...mpany committed to discovering, developing and com..., reported financial results for the fiscal year e...rmasset held $58.4 million in cash, cash equivalen...date and 2009 Highlights ,, RG7128 ,, P...
(Date:11/25/2009)...a., Nov. 25 For many of ...ally the 27 million living with untreated hearing...ys audiologist Cindy Beyer. ,, Dr. Beyer, senio...America,s largest hearing care and hearing aids ...o stress, frustration, and social isolation, "whic...
Breaking Medicine Technology:Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 3Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 4Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Pharmasset Reports Fiscal Year End 2009 Financial Results 9Pharmasset Reports Fiscal Year End 2009 Financial Results 10For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 3Using insects to test for drug safety 56345 1Rate of teen binge drinking cut more than 1 3 by prevention system 56343 1Rate of teen binge drinking cut more than 1 3 by prevention system 56343 2Rate of teen binge drinking cut more than 1 3 by prevention system 56343 3Creation of international health links center 56339 1Creation of international health links center 56339 2
...ata To Be Presented Along With Updated Phase 1 Col...nual Meeting -, SOUTH SAN FRANCISCO, Calif. and C...harmaceuticals, Inc. (Nasdaq: PARD ), a biopharma...ced positive preliminary results,from its ongoing ...,metastatic colorectal cancer (CRC) and updated re...
...nstrates Activity in Combination with Other Target...e of Breast Cancer Settings, - First Phase II dat...GF, pathways with two oral, small molecule tyrosin...strates activity in first-line HER2 (ErbB2) positi...Phase II results combining TYKERB and AVASTIN(R) (...
Other Medicine Technology:Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 2Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 3Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 4Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 5New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 2New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 3New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 4New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 5New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 6New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 7New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 8New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 9New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens 10
(Date:11/27/2009)...al, economic burdens, study predicts , ,... people with diabetes in the United States is expe... predicts. , That would bring the total by 2034... from 23.7 million today. , , At the same time, ...ple, the study also warns, rising from an estimate...
(Date:11/27/2009)...lingual coloring books designed for children ages ...y to educate - inform parents and children alike o...suars to ABC,S and a host of other topics. , ...er 27, 2009 -- Today’s children have enough ... hour of the day, but one of the oldest and simple...
(Date:11/26/2009)... -- With cold and flu season upon us, it,s more im...rol the spread of infections and avoid illness. ,...elves healthy, but to avoid transmitting illness i...ertified in infection-control), nursing director f...spital for Special Surgery (HSS) in Manhattan. ,...
(Date:11/26/2009)...lybdate (TM) has been shown in studies to be effec... caused by an overload of copper, and certain meta...owever, is known about how the drug works at the m...n University researchers now has provided an inval...bound to copper-loaded metallochaperones. The drug...
(Date:11/26/2009)...from the North Pole, Textsanta.net lets parents si... North Pole, AK (PRWEB) --... at the North Pole Santa Claus has added SMS text ... informed of his Christmas progress at the North P...t have identified a large and growing percentage o...
Breaking Medicine News(10 mins):Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2
... obesity may increase a person’s risk of developin...the opposite effect.// In a recent study conduc...s for more than 20 years. They found those who wer...e age were six-times more likely to develop dement...
...as taken its toll on active baby boomers. Arthriti...e the norm //for many of the 78 million middle-age...ctive years ahead. Michael Baroli is finally ...od," he says. "If they don't work, I don't work." ...
...ost common cancer diagnosed among men in the Unite...r. There are several // treatment options, but new...disease altogether. Doctors hope that the dru...stopping testosterone’s conversion to DHT -- a mor...
... have found a way to diagnose melancholic depressi... observe // levels of certain substances in the b...epression marked by insomnia, loss of appetite, an...amate in the brain appear to be linked to melancho...
... might have a partial explanation for the loss of ...c bypass surgery.// In the gastric bypass procedur... the small proximal portion of the stomach, which ...ts who have the surgery show significant early dec...
...tamins too early may result in asthma or food alle...ing the first six months after birth has shown an ... food allergies in children who are only formula f...being male, having a smoker in the house, child ca...
Other Medicine News:
...hieve high-speed productivity in the lab with the ...for pre- and post-analytical sorting requirements....selectively decaps and then sorts primary sample t...ime, labor, and eliminate sample-handling errors. ...
Infant ThermoWrap™
COCOON Disposable Paediatric - Tube
Bair Hugger® Model 537 - Small Lower Body Blanket
Medicine Products: